UK

Driven by our Mission to help Underserved Patients


Global Blood Therapeutics (GBT) is dedicated to discovering, developing and delivering life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease (SCD).


Our goal is to transform the treatment of SCD, an overlooked rare disease that affects an estimated 52,000 people in Europe1, and millions of people throughout the world, particularly those of sub-Saharan African, Hispanic, South Asian, Southern European and Middle Eastern ancestry.


GBT is driven by a sense of urgency to address the needs of the community, such as long-standing racial bias, health inequalities, reduced life expectancy and lack of innovation.


We are advancing next-generation investigational therapies for SCD to improve the care of those living with this devastating lifelong disease.


GBT collaborates with the SCD community, including healthcare professionals, patient advocacy groups and community-based organisations, to increase awareness of SCD and improve access to care for patients.

Facts about Sickle Cell Disease in UK

  • Approximately 15,000 people live with sickle cell disease (SCD).2
  • Approximately 1 in 79 babies carry the sickle cell trait.3
  • Sickle cell disease is estimated to affect 1 in every 2,100 live births in England and it is now the most common genetic condition at birth.4


The prevalence of SCD in Europe is increasing year-on-year, click here for a more detailed overview of the SCD environment in select European countries.

Every day, all of us at GBT share our cultural values:

INNOVATION

Leveraging science and creativity to challenge the status quo

INCLUSION

Creating one team making space for everyone to be heard

ACCOUNTABILITY

Delivering on our commitments and doing the right thing

COMMUNITY

Focused on our mission and devoted to our patients, people and partner

Contact Us :


GBT UK Limited
Tallis House
London
EC4Y 0AB
United Kingdom
info.uk@gbt.com
+44 7827 334671
View on Google Maps

twitter logo linkedin


1EMA: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125 Last accessed July 2021
2NHS England: https://www.england.nhs.uk/wp-content/uploads/2018/08/Specialised-services-for-haemoglobinopathy-care-all-ages.pdf Last accessed July 2021
3Department of Health https://www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-data-report-2018-to-2019/sickle-cell-and-thalassaemia-screening-data-report-2018-to-2019 Last accessed July 2021
4[Sickle Cell Society, 2008; PHE, 2010; NHS Screening Programmes, 2011; Meremikwu and Okomo, 2016]